146 related articles for article (PubMed ID: 29795175)
1. Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial.
Paillassa J; Leguay T; Thomas X; Huguet F; Audrain M; Lheritier V; Vianey-Saban C; Acquaviva-Bourdain C; Pagan C; Dombret H; Ifrah N; Boissel N; Hunault-Berger M
Blood Cancer J; 2018 May; 8(5):45. PubMed ID: 29795175
[No Abstract] [Full Text] [Related]
2. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
3. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
5. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
[TBL] [Abstract][Full Text] [Related]
6. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
7. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
8. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
[TBL] [Abstract][Full Text] [Related]
9. Determination of L-asparagine in biological samples in the presence of L-asparaginase.
Gentili D; Zucchetti M; Conter V; Masera G; D'Incalci M
J Chromatogr B Biomed Appl; 1994 Jul; 657(1):47-52. PubMed ID: 7952083
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
11. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
12. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Strullu M; Corradini N; Audrain M; Orsonneau JL; Bouige D; Thomare P; Vermot-Desroches C; Mansuy A; Legrand A; Rozé JC; Mohty M; Méchinaud F
Leuk Lymphoma; 2010 Aug; 51(8):1464-72. PubMed ID: 20545581
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.
Hunault-Berger M; Leguay T; Huguet F; Leprêtre S; Deconinck E; Ojeda-Uribe M; Bonmati C; Escoffre-Barbe M; Bories P; Himberlin C; Chevallier P; Rousselot P; Reman O; Boulland ML; Lissandre S; Turlure P; Bouscary D; Sanhes L; Legrand O; Lafage-Pochitaloff M; Béné MC; Liens D; Godfrin Y; Ifrah N; Dombret H;
Am J Hematol; 2015 Sep; 90(9):811-8. PubMed ID: 26094614
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia.
van der Sluis I; Möricke A; Escherich G; von Stackelberg A; Holter W; Klingebiel T; Flotho C; Legien S; Tissing W; Bierings M; Guimbal-Schmolck C; Pichlmeier U; Kühnel HJ; Pieters R
Haematologica; 2013 Nov; 98(11):1697-701. PubMed ID: 23753025
[TBL] [Abstract][Full Text] [Related]
15. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
[TBL] [Abstract][Full Text] [Related]
16. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
[TBL] [Abstract][Full Text] [Related]
17. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Wetzler M; Sanford BL; Kurtzberg J; DeOliveira D; Frankel SR; Powell BL; Kolitz JE; Bloomfield CD; Larson RA
Blood; 2007 May; 109(10):4164-7. PubMed ID: 17264295
[TBL] [Abstract][Full Text] [Related]
18. The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.
Watanabe S; Miyake K; Ogawa C; Matsumoto H; Yoshida K; Hirabayashi S; Hasegawa D; Inoue T; Kizu J; Machida R; Ohara A; Hosoya R; Manabe A
Int J Hematol; 2009 Oct; 90(3):347-352. PubMed ID: 19768519
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
Liu C; Kawedia JD; Cheng C; Pei D; Fernandez CA; Cai X; Crews KR; Kaste SC; Panetta JC; Bowman WP; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
Leukemia; 2012 Nov; 26(11):2303-9. PubMed ID: 22484422
[TBL] [Abstract][Full Text] [Related]
20. Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Asselin BL; Fisher V
Clin J Oncol Nurs; 2014 Dec; 18(6):E107-12. PubMed ID: 25427712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]